Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3.37M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
1.07M
-
Shares change
-
+76.8K
-
Total reported value, excl. options
-
$3.66M
-
Value change
-
+$244K
-
Number of buys
-
5
-
Number of sells
-
-6
-
Price
-
$3.42
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q3 2023
21 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q3 2023.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.07M shares
of 3.37M outstanding shares and own 31.85% of the company stock.
Largest 10 shareholders include Slate Path Capital LP (358K shares), MFN Partners Management, LP (169K shares), FMR LLC (165K shares), TYNDALL CAPITAL PARTNERS L P (148K shares), Artal Group S.A. (138K shares), VANGUARD GROUP INC (40.5K shares), GEODE CAPITAL MANAGEMENT, LLC (30.7K shares), BlackRock Inc. (18K shares), ACADIAN ASSET MANAGEMENT LLC (2.24K shares), and Royal Bank of Canada (912 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.